Eli Lilly and Company

Agouron Pharmaceuticals, Inc.

William Joseph Hornback

John E Munroe

Timothy Alan Shepherd

Siegfried Heinz Reich

John Howard Tatlock

Vincent J Kalish

Michael J Rodriguez

Bruce Anthony Dressman

Stephen W Kaldor

James E Fritz

Cynthia Darshini Jesudason

Marlys Hammond

Philip Arthur Hipskind

Richard Todd Pickard

Robert Alan Gadski

Lisa Selsam Beavers

Takako Takakuwa

Grant Mathews Vaught

Don Richard Finley

Scott C Mauldin

Terry Patrick Finn

Esteban Dominguez-Manzanares

Ana Maria Castano Mansanet

Dennis Michael Zimmerman

Hamideh Zarrinmayeh

Zhipei Wu

Joseph Chiou-Chung Tang

Eric George Tromiczak

Delu Jiang

Joseph Matthew Colacino

Jian Eric Hong

Pamela Ann Albaugh

Paul Leslie Ornstein

John H McDonald, Iii

Larry C Blaszczak

Ana Maria Escribano

Freddie Craig Stevens

Serge Louis Boulet

Maria Carmen Fernandez

William David Miller

Gwendolyn K Cook

Michelle Lee Thompson

Michael Scott VanNieuwenhze

Alma Maria Jimenez-Aguado

Kirk Alan Staschke

Frederic Laurent Cordier

Elizabeth Anne Dingess-Hammond

Mark Ayer Muesing

Steven Duane Hatch

Michael J Rodriquez

Larry Gene Huffman

Terry Patrick Eli Lilly And Company Finn

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine&#x2014;H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. 

Histamine H3 receptor agents, preparation and therapeutic uses

The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. (Formula I). 

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine&#x2014;H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor&#x2014;related diseases 

The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. 

The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently &#x2014;(C&#x2014;C) alkyl (optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence &#x2014;H, -halogen, or &#x2014;CH. 

Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses

The present invention relates to thiophene and furan compounds and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression.

Thiophene and furan compounds

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. 

The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.

Pyrrole and pyrazole derivatives as potentiators of glutamate receptors

The present invention relates to AMPA receptor potentiators of Formula I: formulations comprising them, methods for their use, and intermediates useful for their preparation.

AMPA receptor potentiators

The stereospecific synthesis of a glycopeptide using a triply orthogonal protection scheme is described, in particular, the synthesis of N-acetylglucosaminyl-&#x3b2;-[1,4]-N-acetylmuramylmonopeptide and derivatives thereof. The glycopeptide is useful for the preparation of GMDP and related compounds having a glucosaminyl-&#x3b2;-[1,4]-N-acetylmuramic acid disaccharide core.

Glycopeptide and preparation thereof

Method of making HIV protease inhibitors

Compounds useful as intermediates in the preparation of HIV protease inhibitors. These compounds have the following general formula:

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Pharmaceutical compositions containing HIV protease inhibitors and

Anti-viral compounds

Anti-viral method

Growing community of inventors

Fishers, IN, United States of America

William Joseph Hornback